Economia chinesa
In 2025, Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms, totaling US$135.7 billion, up from 94 deals worth US$51.9 billion in 2024. Data released last week by China's National Medical Products Administration (NMPA) shows the number and value of these deals hit record highs, driven by dozens of multibillion-dollar agreements involving Hong Kong and mainland China-listed firms and international giants.
Reportado por IA
While the underperformance of Chinese equities in the last financial quarter warrants scrutiny, overall gains are likely to continue in 2026. Most Wall Street banks remain bullish on Chinese stocks, though some have turned more cautious. China's stock market saw a strong rebound in 2025, with Hong Kong emerging as Asia's top fundraising venue.
Canon Zhongshan Business Machines has shut down its laser printer factory in Zhongshan city, Guangdong province, marking the end of an era. Chinese brands have not only caught up with foreign rivals but have begun to dominate the home market. Production ceased on November 21, with staff handling aftermath tasks.
Reportado por IA
Over the past half-century, Chinese companies have steadily expanded their global reach, though the journey has been winding and often turbulent. With narrowing domestic profits and expanding production capacity, firms are widening overseas footprints in search of lucrative markets. This explainer charts the evolution of China Inc.'s global expansion.